Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Die erste volle Börsenwoche im neuen Jahr hatte es in sich. Nicht nur verzeichneten einige US-Börsenindizes neue Allzeithochs, auch im IPO-Markt drängten sich die Börsenaspiranten auf das Parkett. Gleich 30 Börsengänge konnte die Nasdaq vermelden, die meisten davon allerdings sogenannte "SPACs"
